Biomarkers associated with checkpoint inhibitorsReport as inadecuate

Biomarkers associated with checkpoint inhibitors - Download this document for free, or read online. Document in PDF available to download.

* Corresponding author 1 CHU Pontchaillou Rennes 2 DITEP - Département d’Innovation Thérapeutique et essais précoces 3 UMR 1015 - Immunologie des tumeurs et immunothérapie 4 Stanford University Stanford 5 MiCa - Microenvironnement et cancer

Abstract : Numerous biomarkers may reflect the pharmacodynamics of checkpoint inhibitors and predict their efficacy and-or their toxicity in patients. However, the interest of these biomarkers in clinical practice remains ill-defined and will have to be clarified in future studies. Such biomarkers should help to finely define patients who will benefit most from these costly and potentially toxic drugs.Checkpoint inhibitors CPI, namely anti-CTLA4 and anti-PD1-PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events irAE. Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy pharmacodynamics and clinical benefit and the toxicity irAE of CPIs in patients.

Keywords : suppressor-cells clinical-response expanded access program regulatory t-cells lymphocyte-associated antigen-4 advanced melanoma patients metastatic melanoma ctla-4 blockade ipilimumab treatment cancer-patients

Author: G. Manson - J. Norwood - A. Marabelle - H. Kohrt - R. Houot -



Related documents